ABOUT YOU Holding SE

  • WKN: A3CNK4
  • ISIN: DE000A3CNK42
  • Land: Deutschland

Aktuelle Termine

23.08.22 Hauptversammlung
24.05.22 Veröffentlichung Jahresfinanzbericht
29.03.22 Analystenveranstaltung
18.01.22 Analystenveranstaltung
11.01.22 Veröffentlichung Quartalsmitteilung (Stichtag Q3)
18.11.21 Analystenveranstaltung
17.11.21 Analystenveranstaltung
17.11.21 Analystenveranstaltung
10.11.21 Analystenveranstaltung
09.11.21 Veröffentlichung Halbjahresfinanzbericht
28.09.21 Analystenveranstaltung
22.09.21 Analystenveranstaltung
21.09.21 Analysts' Conference
20.09.21 Analystenveranstaltung
13.09.21 Analystenveranstaltung
10.09.21 Analystenveranstaltung
09.09.21 Analystenveranstaltung
23.07.21 Roadshow
22.07.21 Veröffentlichung Quartalsmitteilung (Stichtag Q1)

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.

29. November 2021